Melanoma clinical trials

The registry lists 3,370 studies for Melanoma across more than 10 countries. 578 are recruiting or about to start. 2,439 of them are mainly about Melanoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 3 narrower conditions too, such as Uveal Melanoma: 3,539 studies, 607 open.

ClinicalTrials.gov finds 3,782 studies for Melanoma. How that becomes 3,370 here

This page counts the studies the registry files under Melanoma, and those it files under no condition that list Melanomathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

3,782Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−168Filed under a narrower condition, counted on its own pageUveal Melanoma 157 · Dysplastic Nevus Syndrome 10
−67List Melanoma as a condition, but the registry did not file them under itMost often written as “Advanced Melanoma” (16), “Clinical Stage III Cutaneous Melanoma AJCC v8” (6), and “Cutaneous Malignant Melanoma” (5). The registry filed them under other conditions only, most often Colorectal Neoplasms (11) and Melanoma, Cutaneous Malignant (10).
−177Match it another way50 name it in the title, 7 in a keyword, and 120 by a synonym or other text the search reads.
3,370The count on this page170 of them list Melanoma in their own words; the registry filed them under no condition.

Get an email when these change. Save the Melanoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 1,570
Terminated: 524
Recruiting: 467
Active, not recruiting: 286
Status unknown: 254
Withdrawn: 119

Phase

Phase 2: 1,424
Phase 1: 1,264
Phase 3: 193
Early Phase 1: 58
Phase 4: 28

Where

United States: 2,048
France: 362
Australia: 285
Germany: 284
Spain: 282
United Kingdom: 269

Who runs them

National Cancer Institute (NCI) (211) · M.D. Anderson Cancer Center (108) · Bristol-Myers Squibb (99) · Memorial Sloan Kettering Cancer Center (67) · Novartis Pharmaceuticals (49) · Hoffmann-La Roche (46) · Mayo Clinic (44) · Pfizer (40)

What is being tested here

Drugs under test in Melanoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Nivolumab	30	19	133
Ipilimumab	20	13	144
Pembrolizumab	19	9	78
Relatlimab	6	2	16
Binimetinib	5	4	30
Cemiplimab	5	1	10
Encorafenib	4	3	27
Lifileucel	4	1	13
Toripalimab	4	1	13
Fianlimab	4	3	7

Drug classes tested here Immune checkpoint inhibitors 79 open · Tyrosine kinase inhibitors (TKIs) 14 open · Alkylating agents 7 open · Antimetabolites 6 open · Antibody-drug conjugates (ADCs) 3 open

Coming up

58phase 3 studies under way

248studies finish main data collection within a year10 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Jan 2027A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma · Phase 3 · Biocad
Jan 2027A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery · Phase 3 · Regeneron Pharmaceuticals
Jan 2027IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma · Phase 3 · IDEAYA Biosciences
Mar 2027A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) · Phase 3 · Regeneron Pharmaceuticals
Mar 2027Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. · Phase 3 · Pierre Fabre Medicament
Apr 2027Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma · Phase 3 · mAbxience Research S.L.
Sep 2027Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma · Phase 3 · University Hospital, Essen
Sep 2027Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma · Phase 3 · Shanghai Kechow Pharma, Inc.
Oct 2027Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy · Phase 3 · Memorial Sloan Kettering Cancer Center
Oct 2027IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) · Phase 3 · Immunocore Ltd

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger. 47 (10%) take children under 18. 2 (<1%) are for women only and 1 (<1%) for men only; 29 (6%) take healthy volunteers.

Recruiting studies that take each age, of 467
Age	Women	Men
10	39 (8%)	38 (8%)
18	451 (97%)	451 (97%)
30	453 (97%)	452 (97%)
40	451 (97%)	450 (96%)
50	449 (96%)	449 (96%)
65	449 (96%)	449 (96%)
75	440 (94%)	440 (94%)
85	407 (87%)	408 (87%)

Across all 3,370 studies, recruiting or not: 10% stop at 75 or younger and 3% at 65; 10% take children; 1% are for women only and <1% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Melanoma studies take

Of 411 phase 1 interventional studies under Melanoma, half reached primary completion within 49 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	49 mo31–76 · 411 studies	46 mo28–66 · 225 studies	52 mo33–82 · 186 studies
Phase 1/2	61 mo42–85 · 220 studies	61 mo41–84 · 135 studies	59 mo47–98 · 85 studies
Phase 2	53 mo32–88 · 383 studies	35 mo26–60 · 106 studies	67 mo41–94 · 277 studies
Phase 3	47 mo30–94 · 95 studies	37 mo25–49 · 64 studies	—
Interventional, no phase	38 mo20–62 · 227 studies	—	39 mo20–62 · 219 studies
Observational	71 mo35–223 · 236 studies	42 mo30–80 · 59 studies	178 mo40–320 · 177 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting8

SI-B036-ST-101 in Advanced/Metastatic Solid TumorsNov 4, 2026NCT07857616
Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial MetastasesNov 2, 2026NCT07444606
A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid TumorsOct 29, 2026NCT07841925
HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma（FASTIL-Mela02）Oct 27, 2026NCT07406724
Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle AnalysisOct 26, 2026NCT07376512

Show 3 more

Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint InhibitorsOct 23, 2026NCT05629546
Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse EventsOct 20, 2026NCT07694414
MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.Oct 13, 2026NCT07574047

Show 1 more

Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a SystemOct 13, 2026NCT07870265

Studies

Recruiting first, then most recently updated. Showing 50 of 3,370. Browse all 3,370 → or search them.